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Abstract
Cancer drug development generally performs in vivo evaluation of treatment effects that have traditionally relied on
detection of morphologic changes. The emergence of new targeted therapies, which may not result in gross mor-
phologic changes, has spurred investigation into more specific imaging methods to quantify response, such as
targeted fluorescent probes and bioluminescent cells. The present study investigated tissue response to docetaxel
or zoledronic acid (ZA) in a mouse model of bony metastasis. Intratibial implantations of breast cancer cells (MDA-
MB-231) were monitored throughout this study using several modalities: molecular resonance imaging (MRI) tumor
volume and apparent diffusion coefficient (ADC), micro-computed tomography (μCT) bone volume, biolumines-
cence imaging (BLI) reporting cancer cell apoptosis, and fluorescence using Osteosense 800 and CatK 680-FAST.
Docetaxel treatment resulted in tumor cell kill reflected by ADC and BLI increases and tumor volume reduction, with
delayed bone recovery seen in μCT prefaced by increased osteoblastic activity (Osteosense 800). In contrast, the
ZA treatment group produced similar values in MRI, BLI, and Osteosense 800 fluorescence imaging readouts when
compared to controls. However, μCT bone volume increased significantly by the first week post-treatment and the
CatK 680-FAST signal was slightly diminished by 4 weeks following ZA treatment. Multimodality imaging provides a
more comprehensive tool for new drug evaluation and efficacy screening through identification of morphology as
well as function and apoptotic signaling.
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Introduction
Bone metastases occur in more than 70% of advanced breast cancer
patients with complications including bone fracture, pain, and spinal
compression [1]. More than 250,000 patient deaths worldwide result
from breast cancer, mainly attributed to metastatic disease [1]. Current
treatments include systemic cytotoxic drugs, as well as bisphospho-
nates used for inhibition of bone loss, and are limited in their efficacy
for combating bony metastasis [2,3]. Much recent research has been
focused on targeted agents that disrupt specific closely involved signal-
ing pathways in cancer. Effects of these treatments can be highly com-
plex, which present challenges for the characterization of treatment
response owing to the numerous mechanisms involved [4]. For exam-
ple, recent studies in skeletal metastases have revealed important inter-
actions between the tumor and its microenvironment [5–9]. It is well
known that bone tissue harbors a latent pool of transforming growth
factor–β (TGF-β) that when released by bone resorption propagates
cancer growth in skeletal regions [2,10–12]. The discovery of this
interdependency has spurred development of new targeted drugs to
inhibit this cycle, resulting in a spectrum of agents targeting various
stages of the cycle including TGF-β receptors in cancer cells, RANK in
osteoclast precursors, cathepsin-K, and bisphosphonates for inhibiting
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osteoclast activity [11]. Conventional anatomic imaging and histologic
techniques for quantifying response to therapy are insufficient for
capturing the time-dependent interactions and targeted mechanisms
of this complex system. Conventional approaches to monitoring cancer
response to therapy are limited, with the most prevalent being changes in
tumor volume followed by quantitative measurements of tissue perfusion
and diffusion. Because of the unconventional action these agents have on
metastatic breast cancer to the bone, a more comprehensive assessment of
tumor biology and response to intervention would provide investigators
developing new targeted agents with improved insights into the compli-
cated interrelationships of the signaling pathways and their role in tumor
growth and cell death.
In this study, a multimodality approach to imaging treatment
response was undertaken in an effort to more fully delineate the under-
lying biologic responses to bisphosphonate and taxane treatment using
a mouse model of established breast cancer metastasis to the bone.
Molecular resonance imaging (MRI) was used to monitor tumor soft
tissue volumetric response and cellularity; micro-computed tomog-
raphy (μCT) was used to monitor bone characteristics; biolumines-
cence imaging (BLI) was used to monitor apoptosis by measuring
caspase-3–linked activation; and fluorescent probes targeting bone
mineralization and cathepsin-K activity were used to provide infor-
mation related to bone remodeling activity. Noninvasive imaging
provided for longitudinal assessment of differential treatment effects
on bone and tumor following administration with docetaxel and
zoledronic acid (ZA). Imaging readouts were able to follow signatures
unique to response of tumor and bone, revealing the capability of
applying imaging modalities to “unmix” the complex biologic responses
to individual therapies, thus providing opportunities for assessing more
complex treatments targeting mixed osteoblastic and osteoclastic
phenotypes. Overall, the application of multiple imaging approaches
described herein provide a more comprehensive and robust process
than any single-modality approach for new drug evaluation and efficacy
screening through delineation of treatment effects on tumor and bone
morphology as well as functional and signaling pathways.
Materials and Methods
Animal Tumor Model
Female severe combined immunodeficiency mice were subject to
intratibial implantation ofMDA-MB-231 breast cancer subline 1833 cells
transfected with a luciferase reporter on caspase-3 (Figure 1, PPOP [13],
Promega Corporation,Madison,WI) in the right leg with 105 cells in 5 μl
of serum-free medium suspension. Briefly, mice were anesthetized with an
intraperitoneal injection of ketamine and then leg hair was removed using
Nair. An empty 0.5-cm3 insulin syringe was used to bore a hole down
into the tibial marrow space through the tibial plateau through which a
Hamilton syringe was then used to insert the cell suspension. A sham
injection ofmedia alonewas performed on the left leg as a surgical control.
Treatments
Once tumor size reached a volume of 10 to 20 mm3 (as measured
by MRI), mice were separated into treatment groups of ZA (n = 16),
docetaxel (n = 7), or control (n = 17). ZA treatment was admin-
istered subcutaneously as 100 μg in 100 μl of phosphate-buffered
saline (PBS, 5 mg/kg) per mouse twice weekly for four treatments,
docetaxel was administered intravenously at a dose of 20 mg/kg
weekly for three cycles, and control mice were administered PBS with
the same schedule as ZA. Control animals treated with 10% ethanol
were also considered but were found not to differ from PBS controls
so are not shown.
Imaging and Analysis
Molecular Resonance Imaging. MRI was performed using a 7-T,
16-cm horizontal bore DirectDrive System (Agilent Technologies,
Palo Alto, CA) with a quadrature mouse head coil (m2m Imaging
Corp, Cleveland, OH). Images of the tumor-bearing leg were
acquired twice weekly starting from the day before treatment initia-
tion. Diffusion-weighted images were acquired using a spin-echo
sequence with navigator echo motion correction and gradient wave-
forms sensitive to isotropic diffusion [14] using the following param-
eters: repetition time/echo time = 4000/37 ms, field of view = 20 ×
20 mm, matrix size = 128 × 64, slice thickness = 0.5 mm, slice num-
ber = 25, and b values (diffusion weighting) of 120 and 1200 s/mm2.
Following image acquisition, data that included manually drawing
volumes of interest on the high diffusion-weighted image to compute
tumor volumes and diffusion values were stored for analysis. Tumor
volumes and apparent diffusion coefficient (ADC) values were quan-
tified over time to monitor tumor burden and cellularity, respectively.
Micro-computed Tomography. μCT imaging was performed
weekly starting from the day before treatment initiation using a
Siemens Inveon System with the following parameters: 80 kVp,
500 μA, 300-ms exposure, 501 projections over 360 degrees, and
49.2-mm field of view (56-μm voxel size). Volumes of interest were
drawn over the tibia from the tibia-fibula junction to the tibial plateau,
measuring mean bone volume and mineral density throughout the
study to monitor bone resorption.
Bioluminescence Imaging. For imaging of the PPOP-transfected
cells, mice were injected with 200 mg/kg luciferin (Promega), and
up to five mice were imaged in a single BLI scan, acquiring a series
of images to find the total photon peak flux over a whole-leg region
of interest (ROI) for each animal. Images were acquired on the day of
treatment initiation and days 7, 10, 14, 21, and 28 afterward. BLI data
Figure 1. Diagram of the split luciferase construct used in this
model. A split-luciferase complex is expressed in the cells with a
DEVD sequence between the N-Luc and C-Luc domains, keeping
the enzyme inactive through steric hindrance. When caspase-3 is
expressed in the cell, signaling the cell to begin apoptotic events,
active caspase-3 cleaves the DEVD sequence from the rest of the
enzyme. Active luciferase then metabolizes luciferin substrate and
emits light.
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were quantified as total photon peak flux normalized by tumor volume
as measured by MRI.
Fluorescence Imaging. Fluorescence images were acquired on an
IVIS Spectrum System (PerkinElmer, Inc, Walther, MA) every other
week using the two probes: Osteosense 800 and CatK 680-FAST
(PerkinElmer, Inc). Fluorescent probes were injected intravenously
24 hours before imaging, and hair was removed from the hind legs
the same day using Nair lotion. The following optical filter sets were
used for each acquisition:
Emission (nm) Emission (nm)
430 500 580 640
675 720 740 760
745 800 820 840
After acquisition, images were spectrally unmixed using Living Image
software (Caliper Life Sciences) to separate the two probe signals
from each other and autofluorescence. ROIs with the same area were
placed over both the left and right legs and signal was measured as
the ratio (right/left) of mean radiant efficiency to account for varia-
tion in fluorophore injection, physiology, and possible accumulation
of fluorescent agent because of the high frequency of imaging.
Statistics. A Student’s t test was used to compare means between
groups at each time point. Results with P < .05 were considered sta-
tistically significant. All plots represent mean ± SEM.
Results
MRI was performed to monitor tumor volume and water diffusivity
(ADC) twice weekly throughout the study (Figure 2). This modality
was able to detect a significant retardation of tumor growth
(Figure 2A) in the docetaxel-treated group by day 6 compared to
the control and ZA-treated groups, which was followed by tumor
shrinkage with no recovery within the study time frame. In addition,
ADC values of the docetaxel-treated group were found to signifi-
cantly increase by day 6 (Figure 2B ), indicating that significant
tumor cell death in the docetaxel group had occurred following treat-
ment initiation. The ZA group however showed no significant differ-
ence from control tumor ADC values over the duration of the study
although both trended downward, indicating that increasing density
or packing of tumor cells occurred during the multifold volumetric
increase in tumor size. Representative ADC map overlays for each
of the animal groups (Figure 2C ) revealed consistently low ADC
values in the control and ZA groups, whereas localized regions in
the docetaxel-treated tumors became elevated before and during
tumor shrinkage.
Figure 2. (A) Plots of percent change in tumor volume for each group show significant cell kill in the docetaxel group but no significant
effect in the ZA group. (B) Plots of percent change in tumor ADC show elevated values in the docetaxel group after day 6 but no sig-
nificant change in the ZA group. (C) Representative ADC overlays show isolated areas of increased ADC in the docetaxel group (red) as
well as a dramatic decrease in tumor volume seen at day 20. Asterisk indicates a significant difference from the control group (P < .05).
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BLI of the PPOP reporter (Figure 3) revealed an increase in caspase-3
activity in the docetaxel group within 1 week of treatment, which
remained elevated until the end of the study. Control and ZA groups
both remained at baseline levels throughout the study, indicating
that no significant apoptotic activation occurred. Representative
bioluminescence images for each of the three groups (Figure 3B )
showed that a stable low level of photons were emitted from the tumor
sites in the control and ZA groups over time, whereas an increase in
photon counts in the docetaxel group occurred (Figure 3B ).
To monitor bone changes with therapy, μCT imaging was per-
formed weekly and bone volume within the proximal tibia was quan-
tified over the 4-week duration of the study (Figure 4A ). Within
1 week of treatment with ZA, a significant increase in bone volume
was detected, which remained elevated throughout the study. The
docetaxel group showed a delayed bone response, with a significant
increase in bone volume observed at week 3. Control mice were
found to have a stable total bone volume until week 3 followed by
significant bone degradation. Representative images (Figure 4B ) show
progressive bone degradation in the control group throughout the
study, whereas the ZA mouse’s bone seemed to have stabilized even
though growth of the soft tissue tumor appears to be fracturing the
bone in certain weakened locations. Docetaxel-treated mice showed
delayed bone response, with significant recovery by week 4.
Fluorescence imaging (FLI) was performed to obtain a more func-
tional assessment of bone remodeling, with Osteosense 800 indicat-
ing the extent of bone reformation and activatable CatK 680-FAST
indicating the level of osteolytic activity. The plots in Figure 5 show
that significant bone remodeling changes occurred at weeks 2 and 4
Figure 3. (A) Plots of overall luminescence of the tumor-bearing leg over time. Values are shown as the percent change of total photon
flux (over a fixed-area ROI) normalized by tumor volume (as measured by MRI). (B) Representative radiance overlays show increased
caspase-3 activity in the docetaxel group and minimal change in the control and ZA groups. Asterisk indicates a significant difference
from the control group (P < .05).
Figure 4. (A) Plots of tumor-bearing bone volume from μCT. The control group remained stable over the first 2 weeks followed by
a sharp decline beginning at week 3. An increase in the ZA group was seen by the first week and remained elevated, whereas a sig-
nificant increase was not seen in the docetaxel group until week 3 and almost reached the ZA group by week 4. (B) Representative
image isosurfaces in the three groups. Controls presented successive bone degradation throughout the study. ZA-treated animals
showed minimal changes in bone structure, with only fracturing caused by tumor growth. Docetaxel-treated animals showed some
initial degradation through week 2 followed by recovery seen by week 4. Asterisk indicates a significant difference from the control
group (P < .05).
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in the docetaxel-treated group, whereas there was no significant
change detected in the ZA or control group. The progressive increase
in relative Osteosense 800 signal for the docetaxel group indicated that
there was a significant amount of bone reformation by week 2, earlier
than the CT-evaluated bone response, which was maintained until the
end of the study. CatK 680-FAST signal also showed a significant re-
duction compared to controls in the docetaxel group by week 4. The
control group showed a progressive increase in CatK 680-FAST signal,
indicating tumor growth and increased activation of osteoclasts. The
ZA group did show attenuated CatK 680-FAST activation, which
would be consistent with the reduction in bone loss seen by CT but
was not found to be significant compared to controls.
Discussion
The goal of this study was to investigate the use of multiple imaging
biomarker readouts to interrogate interrelated biologic responses
involved in the treatment of bony cancers in an effort to provide a
more complete understanding of the overall biologic effects in vivo.
Current preclinical studies rely heavily on histologic analysis, where a
number of subjects must be sacrificed at each time point in the study
to assess tissue responses. However, with the increasing variety of
noninvasive imaging tools available, successful longitudinal studies
may be strategically planned to reduce total subject numbers while
maximizing the amount of information that can be extracted from
each subject. This method will be increasingly useful for the evalua-
tion of new therapies that may have multiple targets and require
simultaneous monitoring of multiple processes. In the case of meta-
static bone disease, assessments of treatments that affect both the soft
tissue tumor and mineralized bone are important because of the
known biologic interactions between the two as well as clinical impli-
cations in avoiding skeletal-related events, e.g., fracture. As newer
treatments may not be directly involved in causing cell death or other
conventionally quantifiable tissue responses, optical imaging tech-
niques can be applied to assess treatment-related alterations in
multiple cellular processes in vivo simultaneously and longitudinally
over time. Optical readouts of treatment effects can be obtained from
activatable and targeted FLI probes as well as genetically engineered
tumor cells whose molecular signaling events can be monitored non-
invasively by BLI, which compliment more traditional imaging tech-
niques such as MRI and CT.
The use of MRI and CT for evaluation of soft tissues and bone,
respectively, has long been established. Quantification of tissue response
to therapy using these imaging modalities has classically been through
morphologic changes such as tumor or bone volume, with the more
recent development of functional imaging techniques such as diffusion
MRI [14–19] and perfusion measurements acquired by MRI or CT
[20–23]. The recent trend in therapeutic research, however, is toward
modification of specific cellular signaling pathways using targeted
agents that may not have such drastic morphologic effects. With these
new agents, conventional imaging approaches may not have enough
sensitivity or specificity to determine treatment effects in vivo. In this
study, we have presented a multimodality approach to evaluate treat-
ment response using readouts obtained through pathway-specific
optical imaging techniques backed by conventional μCT and MRI,
which are clinically relevant modalities that provide more general infor-
mation on morphology and gross tissue characteristics. We evaluated
two treatments representing the extremes of either tumor-specific or
bone-specific therapies to more easily illustrate the separate effects of
these agents on the complex tumor-stromal interaction. Tumor ADC
response has been tested on a broad range of cases and shown to
correlate with cell death and often preclude any detectable change in
tumor volume [14–19], however, ADC alone cannot determine the
mechanism of cell death. The inclusion of caspase-3–coupled bio-
luminescence in this case provides the link between treatment and
the specific mechanism. The significant increase in normalized BLI
signal in the docetaxel group over the controls indicates that, through
caspase-3 signaling, cells are undergoing apoptotic cell death. Tumor
ADC values did not show a significant difference between docetaxel
and control groups before tumor volume. This is attributed to MDA-
MB-231 cell lines aggressiveness and high sensitivity to docetaxel.
FLI results using our two probes shed further light on the bone
remodeling processes resulting from the tumor and treatments. Where
μCT provides a high-resolution view of the current state of the bone,
FLI is sensitive to the balance between processes of bone formation and
erosion. The significant increase in the Osteosense 800 signal and
dampening of the CatK 680-FAST signal for the docetaxel group
indicates that induction of tumor cell kill and subsequent reduction
in tumor burden has inhibited the tumor-stromal interaction, i.e.,
“vicious cycle” [2], and shifted the balance of osteoblastic and osteo-
lytic activities toward recovery. Tumor apoptosis following effective
Figure 5. Bar plots of fluorescent signals in the tumor-bearing leg
from (A) Osteosense 800 and (B) CatK 680-FAST are presented as
values normalized by the non-tumor–bearing leg. The ZA group
showed no significant difference from controls with either fluores-
cent probe, but the docetaxel group showed significant increases
in Osteosense 800 uptake (A, black bar) on weeks 2 and 4 and a
significant drop in CatK 680-FAST signal (B, black bar) on week 4.
Asterisk indicates a significant difference from the control group
(P < .05).
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treatment by docetaxel led to a reduction in osteoclast recruitment and
subsequently fewer cathepsin-K–expressing cells in that region, where
even MDA-MB-231 cells have been shown to express cathepsin-K
[24]. In addition, the disruption of the tumor-stromal interaction
allowed for an up-regulation of osteoblastic activity as evidenced by
an increase in Osteosense 800 signaling. As expected, treatment with
ZA had no effect on tumor burden, suggesting that tumor signaling
to the stroma was undisrupted during treatment. In contrast to what
we observed using docetaxel, ZA did not significantly affect the Osteo-
sense 800 signal ratio that would have been presumed based on the
μCT results where an increase in bone volume was observed. Although
not significant, the CatK 680-FAST signaling was slightly reduced
in the ZA group when compared to controls. This may indicate that
ZA protects the bone by reducing the extent of osteolytic activity, in
essence shifting total bone turnover in the presence of a tumor from
bone erosion to bone formation [14–23,25–30].
When using a strategy for assessing the efficacy of a therapy using
a multimodality imaging approach, it is important to take into account
the limitations of the desired imaging modalities when planning a
study. MRI and CT are both able to capture relatively high-resolution
images, providing easily quantified volume and ADCmeasurements, as
well as being translated to the clinic. These two modalities, however, do
not provide any information about the signals or mechanics of the
biologic system. In contrast, the optical techniques described here
provide detailed information on biologic processes and signaling but
are confined to preclinical use. BLI and FLI are known to present
challenging hurdles for in vivo quantification, such as assumptions of
light attenuation and scattering through tissues, limited spatial resolu-
tion, and error in the injected probe/substrate. In the presented work,
the fluorescent signal in the tumor-bearing leg was normalized by the
signal in the sham leg to account for variability of injection and height-
ened Osteosense 800 signal in the growth plates. The poor image
resolution of FLI complicates matters further by having to contend
with spillover signal from the growth plates. Nevertheless, with an
established imaging protocol for acquiring data, care in image post-
processing, and an appropriate model, these limitations can be over-
come to provide a full picture of the effects of a therapeutic agent on a
tumor-stromal microenvironment.
Overall, the experiments presented here demonstrate the use of
multimodality imaging techniques for detection and quantification
of multiple interrelated biologic processes affected by therapeutic inter-
vention in a model of metastatic bone disease. Although the treatments
were selected on the basis of their current clinical relevance and their
targeted effects on bone or tumor cells, this generalizable approach is
anticipated to be useful in future studies identifying responses to
experimental agents by obtaining a more complete understanding of
the signaling pathways affected. These and other cancer cell lines have
already been successfully engineered to express luciferase linked to
cellular signals such as AKT, TGF-β, c-MET, epidermal growth factor
receptor (EGFR), and others [26,28,29,31,32]. In addition, a wide vari-
ety of in vivo fluorescent agents (activatable and targeted) are already
available, for imaging of many diseases. Selection of optical imaging
agents, cell lines, and other imaging modalities, such as permeability
MRI for measuring tumor vasculature, requires careful evaluation of
which experimental readouts provide the most relevant information for
assessing the efficacy of a novel agent as a single or combination therapy.
In summary, experimental therapeutic agents have traditionally
relied on anatomic and functional imaging readouts of treatment
response. With the emergence of optical imaging approaches includ-
ing reporter cell–based constructs and activatable and targeted exog-
enously administered probes, the interdependence of treatment
responses due to complex tumor-host interactions can be more fully
delineated. BLI and FLI in vivo methods may be tailored to most
diseases and treatment interventions and are complementary to
MRI and CT imaging readouts. The use of a multimodality imaging
strategy is anticipated to provide the pharmaceutical industry with
cost-effective and efficient options for furthering overall drug devel-
opment strategies.
References
[1] Coleman RE (2001). Metastatic bone disease: clinical features, pathophysiology
and treatment strategies. Cancer Treat Rev 27, 165–176.
[2] Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic
opportunities. Nat Rev Cancer 2, 584–593.
[3] Tkaczuk KH (2009). Review of the contemporary cytotoxic and biologic
combinations available for the treatment of metastatic breast cancer. Clin Ther
31(pt 2), 2273–2289.
[4] Korpal M, Yan J, Lu X, Xu S, Lerit DA, and Kang Y (2009). Imaging trans-
forming growth factor-β signaling dynamics and therapeutic response in breast
cancer bone metastasis. Nat Med 15, 960–966.
[5] Casimiro S, Guise TA, and Chirgwin J (2009). The critical role of the bone
microenvironment in cancer metastases. Mol Cell Endocrinol 310, 71–81.
[6] Guise TA (2002). The vicious cycle of bone metastases. J Musculoskelet Neuronal
Interact 2, 570–572.
[7] Joyce JA and Pollard JW (2009). Microenvironmental regulation of metastasis.
Nat Rev Cancer 9, 239–252.
[8] Ooi LL, Zheng Y, Stalgis-Bilinski K, and Dunstan CR (2011). The bone
remodeling environment is a factor in breast cancer bone metastasis. Bone 48,
66–70.
[9] Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, and
Dunstan CR (2007). Inhibition of bone resorption, rather than direct cyto-
toxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin
in a murine model of breast cancer bone metastasis. Bone 40, 471–478.
[10] Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna
M, Peng XH, Chirgwin JM, and Guise TA (2009). Hypoxia and TGF-β drive
breast cancer bone metastases through parallel signaling pathways in tumor cells
and the bone microenvironment. PLoS One 4, e6896.
[11] Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, and Ueno NT (2010).
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev
Clin Oncol 7, 641–651.
[12] Rose AA and Siegel PM (2010). Emerging therapeutic targets in breast cancer
bone metastasis. Future Oncol 6, 55–74.
[13] Galbán S, Jeon YH, Sharkey LM, Hoff BA, Galbán CJ, Ross BD, and
Rehemtulla A (2012). A genetically engineered mouse for imaging of apoptosis
in a tissue specific manner. In Proceedings of the 103rd AACR Annual Meeting,
2012 March 31–April 4. Chicago, IL. Poster session presented at: AACR 2012.
[14] Moffat BA, Hall DE, Stojanovska J, McConville PJ, Moody JB, Chenevert TL,
Rehemtulla A, and Ross BD (2004). Diffusion imaging for evaluation of tumor
therapies in preclinical animal models. MAGMA 17, 249–259.
[15] Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS,
Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging:
an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer
Inst 92, 2029–2036.
[16] Galbán CJ, Bhojani MS, Lee KC, Meyer CR, Van Dort ME, Kuszpit KK,
Koeppe RA, Ranga R, Moffat BA, Johnson TD, et al. (2010). Evaluation of
treatment-associated inflammatory response on diffusion-weighted magnetic
resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission
tomography imaging biomarkers. Clin Cancer Res 16, 1542–1552.
[17] Hamstra DA, Rehemtulla A, and Ross BD (2007). Diffusion magnetic reso-
nance imaging: a biomarker for treatment response in oncology. J Clin Oncol
25, 4104–4109.
[18] Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ,
Johnson TD, Junck L, Robertson PL, Muraszko KM, et al. (2003). Evaluation
of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther
2, 581–587.
[19] Hoff BA, Chenevert TL, Bhojani MS, Kwee TC, Rehemtulla A, Le Bihan D,
Ross BD, and Galbán CJ (2010). Assessment of multiexponential diffusion
420 Multimodality Imaging in a Bone Metastasis Model Hoff et al. Translational Oncology Vol. 5, No. 6, 2012
features as MRI cancer therapy response metrics. Magn Reson Med 64,
1499–1509.
[20] Bauerle T, Bartling S, Berger M, Schmitt-Graff A, Hilbig H, Kauczor HU,
Delorme S, and Kiessling F (2010). Imaging anti-angiogenic treatment response
with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer
bone metastasis. Eur J Radiol 73, 280–287.
[21] Walker-Samuel S, Leach MO, and Collins DJ (2006). Evaluation of response to
treatment using DCE-MRI: the relationship between initial area under the
gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys
Med Biol 51, 3593–3602.
[22] Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ,
Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, et al. (2007).
Integration of quantitative DCE-MRI and ADC mapping to monitor treat-
ment response in human breast cancer: initial results. Magn Reson Imaging
25, 1–13.
[23] Hoff BA, Bhojani MS, Rudge J, Chenevert TL, Meyer CR, Galbán S, Johnson
TD, Leopold JS, Rehemtulla A, Ross BD, et al. (2011). DCE and DW-MRI
monitoring of vascular disruption following VEGF-Trap treatment of a rat
glioma model. NMR Biomed 25, 935–942.
[24] Tomita A, Kasaoka T, Inui T, Toyoshima M, Nishiyama H, Saiki H, Iguchi H,
and Nakajima M (2008). Human breast adenocarcinoma (MDA-231) and
human lung squamous cell carcinoma (Hara) do not have the ability to cause
bone resorption by themselves during the establishment of bone metastasis.
Clin Exp Metastasis 25, 437–444.
[25] Xie BW, Mol IM, Keereweer S, van Beek ER, Que I, Snoeks TJ, Chan A,
Kaijzel EL, and Lowik CW (2012). Dual-wavelength imaging of tumor progres-
sion by activatable and targeting near-infrared fluorescent probes in a bio-
luminescent breast cancer model. PLoS One 7, e31875.
[26] Bhojani MS, Nyati MK, Zhao L, Normolle DP, Ross BD, Lawrence TS, and
Rehemtulla A (2011). Molecular imaging of Akt enables early prediction of
response to molecular targeted therapy. Transl Oncol 4, 122–125.
[27] Coppola JM, Ross BD, and Rehemtulla A (2008). Noninvasive imaging of apo-
ptosis and its application in cancer therapeutics. Clin Cancer Res 14, 2492–2501.
[28] Nyati S, Schinske K, Ray D, Nyati M, Ross BD, and Rehemtulla A (2011). Mo-
lecular imaging of TGFβ-induced Smad2/3 phosphorylation reveals a role for recep-
tor tyrosine kinases in modulating TGFβ signaling. Clin Cancer Res 17, 7424–7439.
[29] Zhang L, Virani S, Zhang Y, Bhojani MS, Burgess TL, Coxon A, Galbán CJ,
Ross BD, and Rehemtulla A (2011). Molecular imaging of c-Met tyrosine
kinase activity. Anal Biochem 412, 1–8.
[30] Galbán CJ, Galbán S, Van Dort ME, Luker GD, Bhojani MS, Rehemtulla A,
and Ross BD (2010). Applications of molecular imaging. Prog Mol Biol Transl
Sci 95, 237–298.
[31] Khan AP, Contessa JN, Nyati MK, Ross BD, and Rehemtulla A (2011).
Molecular imaging of epidermal growth factor receptor kinase activity. Anal
Biochem 417, 57–64.
[32] Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, Ross BD,
and Rehemtulla A (2007). Molecular imaging of Akt kinase activity. Nat Med
13, 1114–1119.
Translational Oncology Vol. 5, No. 6, 2012 Multimodality Imaging in a Bone Metastasis Model Hoff et al. 421
